.png){kind=icon}
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
Posters
Evaluation of the Immune Response Following Treatment with Anti-CTLA-4 Antibody, Radiation Therapy or the Combination in a Murine Model of Breast Cancer
Breast cancers are considered poorly immunogenic tumors, however, several approaches utilizing immunotherapies are being undertaken in the clinic to evaluate their potential for improving outcomes. Radiation therapy (RT) is a highly utilized clinical treatment modality in breast cancer. Radiation is known to modify the tumor microenvironment, induce cytokines and chemokines, and has been shown to potentially synergize with immunotherapies. During AACR's Annual Meeting 2016, Maryland Franklin, PhD, Vice President, Scientific Development, presented her poster session on this subject. The aim of the work was to evaluate the possible synergy between RT and anti‐CTLA‐4 therapy in a murine model of breast cancer.
